Find and Pitch Jounalists, Get Your Story Covered

Tags: startups ai evs layoffs ransomware

	Profile	Recent Articles on Subject
1	Michael Gibney Pharma Voice Teacher of English. Teacher of politics. Santiago, Chile educationpolitics	Tariffs raise concern among generic drugmakers, and advocacy groups are seeking exemptions - 24 days ago With uncertainty roiling Big Pharma, execs are placing lower-risk bets - 25 days ago Will 2025 mark pharma’s pivot to bigger deals after years of lackluster M&A? - about 2 months ago How pharma was instrumental in President Jimmy Carter’s global health efforts - about 2 months ago How Astellas juggles the moving parts of cancer precision medicine development - 3 months ago Big Pharma earnings hang hope on the next generation of blockbusters - 4 months ago 2024 PharmaVoice 100s: Cell and Gene Therapy Pioneers - 4 months ago Why pharma megamergers may become a relic of the past - 4 months ago 2024 PharmaVoice 100s: Biotech Pathfinders - 4 months ago Top pharma and biotech conferences 2025 - 5 months ago Has pharma emerged from the ‘age of uncertainty’? - 8 months ago Avoiding the pharma ‘junk pile’ with launch readiness, pipeline rigor and ‘quick kills’ - 9 months ago 3 up-and-coming US biotech hotspots - 10 months ago How pharma’s surging M&A is impacting the industry’s tech sector - 11 months ago How to make 2024 a banner year for biopharma, despite the headwinds - about 1 year ago Pharma’s financial market will be a tale of two cities in 2024 - about 1 year ago Real Chemistry’s CEO on biopharma’s outlook in 2024 - about 1 year ago How Big Pharma keeps the oncology engines hot with a host of strategies - over 1 year ago
2	Meagan Parrish Pharma Voice Senior editor @industrydive. Pharma world follower. Wisconsin, USA pharmaceuticalsjournalismparenting	As financial headwinds pick up, pharmas are aiming to squeeze more ROI from their R&D - 26 days ago Pharma’s forecast for 2025: Sowing seeds of a rebound - about 1 month ago Musk’s rare disease torpedo, hospitals’ pharma fix and other policies leaders are tracking - about 2 months ago The ability to pivot will be ‘key’ as pharma’s tariff threat looms - about 2 months ago PharmaVoice’s Crystal Ball: The industry’s AI future - about 2 months ago 3 closely watched drugs that failed in the clinic - 3 months ago Trump’s tariffs could put more pressure on the U.S. to produce generic drugs. Are we ready? - 3 months ago Pharma takes aim at a wily foe — the Epstein-Barr virus - 4 months ago 2024 PharmaVoice 100s: Rare Disease Warriors - 4 months ago 2024 PharmaVoice 100s: Trailblazers - 5 months ago What 3 layoff stories reveal about pharma’s troubles - 6 months ago Pharma’s ‘it’ therapy — a new drug class gaining steam - 6 months ago Pharma’s R&D gamble: picking pipeline winners in a risky field - 9 months ago Where competition is heating up in pharma - 9 months ago The biggest questions hanging over pharma in 2024 - about 1 year ago Pharma execs sound off on trends and policies they’re tracking in 2024 - about 1 year ago PharmaVoice’s Crystal Ball: What’s next in drug innovation and clinical trials - about 1 year ago PharmaVoice 100s: Entrepreneurs - over 1 year ago PharmaVoice 100s: Clinical trial gurus - over 1 year ago
3	Frank Vinluan MedCity News Medical innovation tracker. MedCity, USA medicalinnovation	Novo Nordisk Adds to Manufacturing Capacity, Pumping Billions Into New Rare Disease Site - 3 months ago Eli Lilly Plans $4.5B Medicine Foundry to Foster Innovations in Drug Manufacturing - 5 months ago AstraZeneca Plans $1.5B Manufacturing Site for Global Production of ADC Cancer Drugs - 10 months ago
4	Amy Baxter Pharma Voice Scientist, inventor, former pediatrician. Atlanta, Georgia pain relieftechnologyinnovation	Oncology, obesity and more: Where pharma R&D is headed in 2025 - 3 months ago From Mr. Mucus to the Super Bowl, pharma tries offbeat marketing strategies - 4 months ago 2024 PharmaVoice 100s: Tech and AI Wizards - 4 months ago Can BioNTech sustain a post-COVID mRNA pipeline? Oncology is the next hope. - 7 months ago Behind the powerful computations, AI’s role in pharma is still beset by challenges - 9 months ago After ‘tragic’ bacterial outbreak, lawmakers press FDA to step up foreign inspections - about 1 year ago Pharma CFOs need R&D vigilance in tough economic times - about 1 year ago
5	Ed Silverman STAT News Pharmalot columnist. Senior writer at STATnews. pharmaceutical industry	STAT+: Pharmalittle: We’re reading about GSK leaving BIO, an AbbVie schizophrenia drug failing, and more - 4 months ago STAT+: Pharmalittle: We’re reading about pharma risks in China, mitigating shortages, and more - 4 months ago STAT+: Pharmalittle: We’re reading about Moderna R&D cuts, Lilly plant investments and more - 6 months ago STAT+: Major generic maker Aurobindo cuts production at a key plant amid concerns over shortages - about 1 year ago STAT+: Pharmalittle: We are reading about Catalent concerns, a congressional hearing, and more - about 1 year ago STAT+: Pharmalittle: We’re reading about FDA’s syphillis-drug plan, India’s manufacturer-inspection demands, and more - about 1 year ago STAT+: FDA efforts to oversee foreign drug manufacturing remain inadequate to ensure safety, analysis finds - about 1 year ago STAT+: FDA cites Dr. Reddy’s for quality control problems at a biologics plant - over 1 year ago STAT+: Pharmalittle: Novo Nordisk to spend $6 billion to boost production; FDA okays world’s first vaccine for chikungunya - over 1 year ago STAT+: Pharmalittle: Pharma moves closer to a pricing deal with U.K.; FDA to review AstraZeneca request for self-administered flu vax - over 1 year ago STAT+: Pharmalittle: Weight-loss drugs fuel boom for firms that fill syringes; employers that cover obesity drug may double in 2024 - over 1 year ago STAT+: Pharmalittle: FDA finds problems at Novo’s main U.S. factory; polarizing ALS drug heads for FDA scrutiny - over 1 year ago
6	Associated Press MedPage Today Explains healthcare complexities. Not endorsements. New York, New York Healthcare journalism	Nearly 2,000 Pharmaceutical Plants Are Overdue for FDA Checks After COVID Delays - 6 months ago
7	Allison DeAngelis STAT News Reporter at STAT. Formerly Insider, BBJ. biopharmastartupsventure capital	STAT+: Novartis to spend $200 million in further bid to boost radiopharma manufacturing, market dominance - 6 months ago
8	PharmaTimes PharmaTimes PharmaTimes Media Ltd. Digital health news. Surrey, United Kingdom pharmahealthdigital healthmhealthNHSmarketingcommunicationsclinicaljobsMSL	eXmoor pharma’s manufacturing facility receives licence from MHRA - 7 months ago 2024 - about 1 year ago
9	Kelly Bilodeau Pharma Voice Mom, wife, freelance writer. writing	Kite’s next-gen CAR-T aims include quicker production and more disease targets - about 1 year ago Pharma takes a gut check of microbiome drugs - about 1 year ago What are pharma’s next blockbusters? - about 1 year ago Oncology drugmakers seek the sweet spot between efficacy and tolerability - about 1 year ago From the rainforest to Wall Street — Jaguar Health’s big play for revitalization - over 1 year ago
10	John Pinching PharmaTimes Next-gen biopharma company. La Jolla, California biopharmadrugsdevices	Years and years - about 1 year ago

Journalists covering pharma manufacturing